Page results
-
Today is International Clinical Trials Day, an important day on the UCLH calendar because research is an integral part of UCLH’s mission.
-
Two UCLH nurses who have dedicated their entire career to the NHS were invited to attend a VE Day celebration concert last Thursday.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
T16 North is a specialist adult haematology inpatient ward dedicated to providing high-quality care for patients with a wide range of blood disorders.
-
A new scan could improve how millions of people with high blood pressure are treated, suggests a new study led by UCL and conducted at UCLH.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
Acute loss of sense of smell should be considered globally as a criterion for self-isolation, testing, and contact tracing for Covid-19 infection according to researchers at UCLH and UCL.
-
The aim of this page is to provide you with information about flow-diverting stents and how they are used to treat cerebral (brain) aneurysms.
-
Elderly patients suffering the most common type of heart attack may benefit from more invasive treatment, new research involving UCLH has shown.
File results
-
FOI/2023/0142 - Treatment of breast cancer
-
FOI/2023/0143 - Immunoassay Analysers at Trust
-
FOI/2023/0145 - Waiting times for consultant-led treatment, inpatient and outpatients
-
FOI/2023/0152 - Wheelchair associated services
-
FOI/2023/0155 - Patient transport policy
-
FOI/2023/0156 - Digital sepsis alerts for obstetric patients
-
FOI/2023/0159 - Local treatment guidelines for Atopic Dermatitis (Atopic Eczema)
-
FOI/2023/0162 - ICT and Procurement strategy and organisational charts
-
FOI/2023/0174 - Integration Engine (IE) within Trust's IT estate
-
FOI/2023/0175 - Treatment for Myelofibrosis